INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

EDITEditas Medicine, Inc.

CIK 0001650664

EDGAR filingsOpen in network
Disclosed transactions8
Buys / sells0 / 6
Max Insider Score15
Connections6with evidence

EDIT · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
OS
Ory Daniel ScottEVP, Chief Medical Officer
EDITEditas Medicine, Inc.
Grant or award
A—
950.0K sh
Sep 8, 2026Sep 9, 2026
traded Sep 8, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Ory Daniel ScottEVP, Chief Medical Officer · Sep 9, 2026
  • ← Insider ofevidence
    Ellinor Patrick Thomas IIDirector · Aug 7, 2026
  • ← Insider ofevidence
    O'Neill Gilmore NeilDirector, CEO · Dec 4, 2025
11
BL
Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER
EDITEditas Medicine, Inc.
Open-market sale · 10b5-1 plan
SELL
$2,153
709 sh
Sep 3, 2026
Sep 4, 2026
traded Sep 3, 2026
+1d
SEC FORM 4

Evidence

11
PA
Parison AmySVP, Chief Financial Officer
EDITEditas Medicine, Inc.
Open-market sale · 10b5-1 plan
SELL$1,376
453 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

11
ON
O'Neill Gilmore NeilDirector, CEO
EDITEditas Medicine, Inc.
Open-market sale · 10b5-1 plan
SELL$16K
5,124 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

9
ET
Ellinor Patrick Thomas IIDirector
EDITEditas Medicine, Inc.
Grant or award
A—
103.4K sh
Aug 6, 2026Aug 7, 2026
traded Aug 6, 2026
+1dSEC FORM 4

Evidence

15
BL
Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER
EDITEditas Medicine, Inc.
Open-market sale · 10b5-1 plan
SELL$1,535
713 sh
Dec 3, 2025Dec 4, 2025
traded Dec 3, 2025
+1dSEC FORM 4

Evidence

15
PA
Parison AmySVP, Chief Financial Officer
EDITEditas Medicine, Inc.
Open-market sale · 10b5-1 plan
SELL$993
461 sh
Dec 3, 2025Dec 4, 2025
traded Dec 3, 2025
+1dSEC FORM 4

Evidence

15
ON
O'Neill Gilmore NeilDirector, CEO
EDITEditas Medicine, Inc.
Open-market sale · 10b5-1 plan
SELL$12K
5,603 sh
Dec 3, 2025Dec 4, 2025
traded Dec 3, 2025
+1dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Parison AmySVP, Chief Financial Officer · Dec 4, 2025
  • ← Insider ofevidence
    Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER · Dec 4, 2025